Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting Phase 3 Interventional Study
Ischemic Stroke
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
900 (estimated)
Sponsor
Kafrelsheikh University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with large-vessel minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are n…
Contacts

mohamed G. Zeinhom, MD

2001009606828

mohamed_gomaa@med.kfs.edu.eg

CONTACT

sherihan R. ahmed, MD

2001113432342

sherihan_rezq@med.kfs.edu.eg

CONTACT